Physician profile
David Helton
NPI 1235195868
$1,403.06
in general payments reported to CMS, 2019-2025
24 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.45 · 2022: $249 · 2023: $274 · 2024: $394 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $172.56 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $172.52 | 2021-2025 | |
| Abbott Laboratories | $145.23 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $140.17 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $123.52 | 2023-2025 | Farxiga, Airsupra |
| Pfizer INC. | $77.87 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.26 | 2022-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $75.80 | 2024-2025 | Rexulti |
| Amgen INC. | $58.21 | 2023-2024 | Otezla, Repatha, Prolia |
| Biogen, INC. | $43.34 | 2024-2025 | Skyclarys |
| Antares Pharma, INC. | $36.47 | 2022-2025 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $32.62 | 2022 | |
| Merck Sharp & Dohme LLC | $28.54 | 2022 | |
| Exact Sciences Corporation | $27.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $26.51 | 2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.76 | 2024 | |
| Glaxosmithkline, LLC. | $23.28 | 2024 | Arexvy, Shingrix |
| Neurocrine Biosciences, INC. | $22.93 | 2024 | Ingrezza |
| Amarin Pharma, INC. | $19.79 | 2021 | |
| Boston Scientific Corporation | $17.84 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.30 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $14.36 | 2023 | Quviviq |
| Astellas Pharma US INC | $13.84 | 2024 | Veozah |
| Eisai INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Helton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.